Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma.

Molecular oncology·2026
Same author

[Facial fillers: evidence base, anatomical principles, materials, risks, techniques, and future perspectives].

HNO·2026
Same author

Fibroblast activation protein inhibitor-PET/CT in lung cancer: a prospective single-center study with histopathological correlation of fibroblast activation protein expression.

International journal of clinical oncology·2026
Same author

Disease-specificity in correlations between speech audiometry, hearing-related quality of life, and varying calculation methods for pure tone average in middle ear diseases.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC.

BMC cancer·2026
Same author

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Related Experiment Video

Updated: Jan 7, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K

Current status of FAP therapy in solid tumors.

Sophie C Siegmund1, Emil Novruzov2, Eduards Mamlins2

  • 1Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.

Seminars in Nuclear Medicine
|December 27, 2025
PubMed
Summary

Fibroblast activation protein (FAP) targeted imaging complements FDG PET/CT for improved cancer diagnosis, especially in tumors with low glucose metabolism. FAP theranostics show promise for future cancer therapy, offering new hope for systemic disease treatment.

Keywords:
(177)LuCancer-associated fibroblastsFAPIFibroblast activation proteinRadioligand therapySolid tumorsTheranostics

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Related Experiment Videos

Last Updated: Jan 7, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.0K
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Area of Science:

  • Nuclear medicine and molecular imaging
  • Oncology and cancer diagnostics
  • Radiopharmaceutical development

Background:

  • Fibroblast activation protein (FAP) ligands are emerging as novel radiopharmaceuticals for cancer imaging and therapy.
  • FAP-targeted imaging, including FAPI PET/CT, is increasingly recognized as a valuable complement to established FDG PET/CT.
  • While FDG PET/CT is standard, FAP imaging addresses limitations in detecting tumors with low glucose metabolism.

Purpose of the Study:

  • To review recent advancements in FAP-targeted radiopharmaceuticals for both imaging and therapeutic applications in oncology.
  • To highlight the complementary role of FAP imaging alongside FDG PET/CT in specific cancer subtypes.
  • To discuss the current status and future potential of FAP theranostics in cancer treatment.

Main Methods:

  • Review of current literature on FAP-ligands, including small molecules (e.g., FAPI-46, FAPI-74) and peptides (e.g., FAP-2286).
  • Analysis of clinical applications and ongoing trials for FAPI PET/CT and SPECT imaging.
  • Evaluation of FAP-derivatives in early-stage therapeutic development (theranostics).

Main Results:

  • FAPI PET/CT has demonstrated success in imaging various cancers like pancreatic, gastroesophageal, and lung adenocarcinomas, often outperforming FDG PET/CT in specific cases.
  • Several FAP imaging agents (e.g., FAPI-04, FAPI-46, FAPI-74, FAPI-34) are already in clinical practice.
  • FAP-targeted therapeutics are in early clinical trials (Phase I), showing potential for treating systemic diseases.

Conclusions:

  • FAP-targeted imaging is a valuable tool that enhances diagnostic accuracy by complementing FDG PET/CT, particularly in challenging tumor types.
  • FAP theranostics represent a promising frontier for cancer treatment, offering innovative therapeutic strategies beyond standard care.
  • Continued research and clinical trials are crucial for realizing the full potential of FAP-based theranostics in personalized oncology.